Targeted cancer therapy: choosing the right assay to assess PARP inhibitors

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid TumorsПодробнее

PARP Inhibitors: Assessing the Clinical Trial LandscapeПодробнее

Mechanisms of PARP Inhibition: A Mode of Targeted Cancer TreatmentПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

Understanding the Biological Targets of PARP InhibitorsПодробнее

Choosing the correct PARP inhibitor for prostate cancerПодробнее

Optimizing the Use of PARP Inhibitors in Ovarian CancerПодробнее

Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian CancerПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

Enhancing Personalized Medicine in Ovarian Cancer: Advances in PARP Inhibition and Novel ModalitiesПодробнее

Practical Use of PARP Inhibitors in Ovarian CancerПодробнее

Characterization of a PARP Inhibitor Biomarker for Cancer Therapy (AACR)Подробнее

Expert Perspectives: The Clinical Potential of PARP Inhibitors in Ovarian CancerПодробнее

Role of PARP Inhibitors in Prostate CancerПодробнее

Castration Resistant Prostate Cancer: Diagnosis & Testing Considerations With Use of PARP InhibitorsПодробнее

Managed Care Implications of the Expanding Role of PARP Inhibitors in OncologyПодробнее

Understanding the Side Effects of PARP InhibitorsПодробнее

The Role of PARP Inhibitors in Advanced Prostate CancerПодробнее

How PARP inhibitors (PARPi) workПодробнее